MedTrace Logo

A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer

NCT05998941 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-11-22

No results posted yet for this study

Summary

This study used a single-arm, open phase II multicenter trial design. All eligible subjects received TQB2868 plus platinum-based chemotherapy with or without bevacizumab. A total of 39 subjects will be enrolled.

Conditions

Interventions

DRUG

TQB2868 injection

TQB2868 injection is an anti-programmed cell death protein 1 (PD-1)/ transforming growth factor-β (TGF-β) dual-function fusion protein.

DRUG

Paclitaxel injection

Paclitaxel injection prevents depolymerization of microtubules, inhibits mitosis, and hinders normal cell division.

DRUG

Cisplatin injection

Cisplatin injection can inhibit the DNA replication process of cancer cells

DRUG

Carboplatin injection

Carboplatin injection acts directly on DNA, thus inhibiting the vigorous division of tumor cells.

DRUG

Bevacizumab injection

Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF).

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-31
Primary Completion
2025-02-28
Completion
2025-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05998941 on ClinicalTrials.gov